EP3579860A4 - TRAILshort ANTIBODY AND METHODS OF USE - Google Patents
TRAILshort ANTIBODY AND METHODS OF USE Download PDFInfo
- Publication number
- EP3579860A4 EP3579860A4 EP18751393.2A EP18751393A EP3579860A4 EP 3579860 A4 EP3579860 A4 EP 3579860A4 EP 18751393 A EP18751393 A EP 18751393A EP 3579860 A4 EP3579860 A4 EP 3579860A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- trailshort
- antibody
- methods
- trailshort antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762457614P | 2017-02-10 | 2017-02-10 | |
US201762512627P | 2017-05-30 | 2017-05-30 | |
PCT/US2018/017385 WO2018148383A1 (en) | 2017-02-10 | 2018-02-08 | TRAILshort ANTIBODY AND METHODS OF USE |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3579860A1 EP3579860A1 (en) | 2019-12-18 |
EP3579860A4 true EP3579860A4 (en) | 2020-12-09 |
Family
ID=63107013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18751393.2A Pending EP3579860A4 (en) | 2017-02-10 | 2018-02-08 | TRAILshort ANTIBODY AND METHODS OF USE |
Country Status (8)
Country | Link |
---|---|
US (2) | US11136402B2 (en) |
EP (1) | EP3579860A4 (en) |
JP (2) | JP7132230B2 (en) |
CN (1) | CN110494152B (en) |
AU (1) | AU2018219864A1 (en) |
CA (1) | CA3053247A1 (en) |
IL (1) | IL268568B2 (en) |
WO (1) | WO2018148383A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109641041A (en) | 2016-06-15 | 2019-04-16 | 西奈山伊坎医学院 | Influenza virus haemagglutinin albumen and application thereof |
CA3058652A1 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
EP3959216A4 (en) * | 2019-04-24 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
WO2023235453A1 (en) * | 2022-06-03 | 2023-12-07 | Mayo Foundation For Medical Education And Research | Methods and materials for modulating t cell activation using trailshort polypeptides |
WO2023250127A1 (en) * | 2022-06-24 | 2023-12-28 | Mayo Foundation For Medical Education And Research | Treating cancer with chimeric antigen receptors that bind to trailshort polypeptides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150218274A1 (en) * | 2014-01-31 | 2015-08-06 | Novartis Ag | Antibody molecules to tim-3 and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US6284236B1 (en) * | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
IL136156A0 (en) * | 2000-05-16 | 2001-05-20 | Compugen Ltd | Sequences of trail variants |
US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
WO2008088582A2 (en) * | 2006-08-04 | 2008-07-24 | Mayo Foundation For Medical Education And Research | Methods and materials related to trail isoforms |
KR100804126B1 (en) * | 2007-02-09 | 2008-02-19 | 아주대학교산학협력단 | 1 Monovalent Human Monoclonal Antibody Specifically Binding to Receptor of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Antigen-Binding Fragment Thereof |
CL2010000019A1 (en) * | 2010-01-11 | 2010-06-11 | Univ Chile | Monoclonal antibody against human tnf and its fragments, nucleotide sequences that encode it, expression vector and cells containing them, compositions and kit comprising the antibody, use thereof and method for obtaining it. |
TWI728373B (en) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | Antibodies and methods of use |
-
2018
- 2018-02-08 AU AU2018219864A patent/AU2018219864A1/en active Pending
- 2018-02-08 CA CA3053247A patent/CA3053247A1/en active Pending
- 2018-02-08 US US16/485,056 patent/US11136402B2/en active Active
- 2018-02-08 JP JP2019543315A patent/JP7132230B2/en active Active
- 2018-02-08 EP EP18751393.2A patent/EP3579860A4/en active Pending
- 2018-02-08 WO PCT/US2018/017385 patent/WO2018148383A1/en unknown
- 2018-02-08 CN CN201880024112.7A patent/CN110494152B/en active Active
- 2018-02-08 IL IL268568A patent/IL268568B2/en unknown
-
2021
- 2021-08-24 US US17/410,832 patent/US20220127370A1/en active Pending
-
2022
- 2022-08-25 JP JP2022134136A patent/JP2022169711A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150218274A1 (en) * | 2014-01-31 | 2015-08-06 | Novartis Ag | Antibody molecules to tim-3 and uses thereof |
Non-Patent Citations (2)
Title |
---|
A D BADLEY ET AL: "Altering cell death pathways as an approach to cure HIV infection", CELL DEATH AND DISEASE, vol. 4, no. 7, 1 July 2013 (2013-07-01), pages e718, XP055363172, DOI: 10.1038/cddis.2013.248 * |
BARBLU LUCIE ET AL: "Reduction of death receptor 5 expression and apoptosis of CD4+ T cells from HIV controllers", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 155, no. 1, 7 August 2014 (2014-08-07), pages 17 - 26, XP029079225, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2014.07.010 * |
Also Published As
Publication number | Publication date |
---|---|
IL268568B1 (en) | 2023-11-01 |
CN110494152B (en) | 2024-04-09 |
EP3579860A1 (en) | 2019-12-18 |
US20190367626A1 (en) | 2019-12-05 |
US11136402B2 (en) | 2021-10-05 |
CN110494152A (en) | 2019-11-22 |
IL268568B2 (en) | 2024-03-01 |
IL268568A (en) | 2019-09-26 |
US20220127370A1 (en) | 2022-04-28 |
WO2018148383A1 (en) | 2018-08-16 |
JP7132230B2 (en) | 2022-09-06 |
JP2020507580A (en) | 2020-03-12 |
CA3053247A1 (en) | 2018-08-16 |
AU2018219864A1 (en) | 2019-08-29 |
JP2022169711A (en) | 2022-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3515478A4 (en) | Antibodies for siglec-15 and methods of use thereof | |
PL3618863T3 (en) | Anti-tigit antibodies and methods of use thereof | |
EP3383430A4 (en) | Antibodies and methods of use thereof | |
ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
EP3280441A4 (en) | Anti-sortilin antibodies and methods of use thereof | |
EP3383431A4 (en) | Anti-gitr antibodies and methods of use thereof | |
EP3645742A4 (en) | Anti-ror1 antibodies and methods of making and using thereof | |
EP3472200A4 (en) | Anti-myostatin antibodies and methods of use | |
EP3852805A4 (en) | Anti-lilrb2 antibodies and methods of use thereof | |
EP3383917A4 (en) | Novel anti-claudin antibodies and methods of use | |
EP3478723A4 (en) | Pd-l1-specific antibodies and methods of using the same | |
EP3728323A4 (en) | Anti-frizzled antibodies and methods of use | |
EP3675906A4 (en) | Anti-tm4sf1 antibodies and methods of using same | |
EP3559042A4 (en) | Anti-lilrb3 antibodies and methods of use thereof | |
EP3436476A4 (en) | Anti-ryk antibodies and methods of using the same | |
EP3625253A4 (en) | Activatable antibodies and methods of use thereof | |
EP3280440A4 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
EP3525583A4 (en) | Anti-c1s antibodies and methods of use thereof | |
EP3710589A4 (en) | Anti-c1s antibodies and methods of use | |
EP3684819A4 (en) | Anti-ykl40 antibodies and methods of use | |
EP3579860A4 (en) | TRAILshort ANTIBODY AND METHODS OF USE | |
EP3731867A4 (en) | Anti-lrp5/6 antibodies and methods of use | |
EP3635000A4 (en) | Manabodies and methods of using | |
IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
EP3642231A4 (en) | Anti-vista antibodies and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190910 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40019879 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201110 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/02 20060101AFI20201104BHEP Ipc: A61K 39/395 20060101ALI20201104BHEP Ipc: C12N 5/10 20060101ALI20201104BHEP Ipc: C12N 1/15 20060101ALI20201104BHEP Ipc: A61P 31/18 20060101ALI20201104BHEP Ipc: A61K 38/16 20060101ALI20201104BHEP Ipc: C12N 1/19 20060101ALI20201104BHEP Ipc: A61K 38/08 20190101ALI20201104BHEP Ipc: A61P 35/00 20060101ALI20201104BHEP Ipc: C12N 15/63 20060101ALI20201104BHEP Ipc: C12N 1/21 20060101ALI20201104BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230418 |